United States· US:50474-983_48d5f5c1-c45c-cb63-e063-6394a90a31c8
RYSTIGGO
A rozanolixizumab product containing rozanolixizumab, registered in United States by UCB, Inc.. The same ATC class is registered in 7 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC L04AL02 (rozanolixizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AL02
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ROZANOLIXIZUMAB
- Manufacturer
- UCB, Inc.
- Country
- United States (US)
- ATC code
- L04AL02
- ATC class
- Rozanolixizumab
- Defined daily dose
- 80 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1150474983861 VIAL, GLASS in 1 CARTON (50474-983-86) / 6 mL in 1 VIAL, GLASS
- ndc1150474-983-86
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceRYSTIGGO 140 mg/mL, solution injectableUCB PHARMA BELGIQUE
- IrelandRystiggo 140 mg/ml solution for injectionUCB Pharma S.A.
- NetherlandsRystiggo 140 mg/ml oplossing voor injectieUCB Pharma S.A.
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- BelgiumRystiggo 140 mg/mlUCB Pharma
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
- Japanロザノリキシズマブ（遺伝子組換え）ユーシービージャパン
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a54942ad-778a-44ad-beed-c408bad6d308 GET /v1/drugs/a54942ad-778a-44ad-beed-c408bad6d308?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "140",
"substance": "ROZANOLIXIZUMAB",
"productndc": "50474-983",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761286",
"marketing_category": "BLA"
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.